Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1

Conditions

Lymphoma 2Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Cyclophosphamide 447Rituximab 406Etoposide 225Vincristine 217Doxorubicin 204Filgrastim 201Prednisone 178Cytarabine 160Radiotherapy 152fludarabine phosphate 148Methotrexate 137Peripheral Blood Stem Cell Transplantation 130Melphalan 128fludarabine 116Busulfan 101Dexamethasone 93Tacrolimus 76Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 72Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 63Bendamustine Hydrochloride 63Lenalidomide 62Cyclosporine 62Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × BAY 1895344 × Lymphoid × Clear all
NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
31 enrolled 14 charts
LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

NCT03188965 2023-10-11

First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

Bayer

Phase 1 Completed
229 enrolled
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡